Home > News > Content
Orlistat Wins The Nation's First Weight Loss Drug OTC Certification
Dec 16, 2016

Orlistat wins the nation's first weight loss drug OTC certification

Recently, the European Medicines Agency (EMA) completed an assessment of the safety of orlistat-containing drugs. The evaluation report stated that for obese or overweight patients with a body mass index (BMI) of 28 kg/well, use Orlistus. His benefits outweigh the risks and can be used with confidence.

Recognized by the European Medicines Agency, Orlistat shocked the weight loss market

In recent years, the size of obese people in China has grown rapidly. It has been reported that in 1982, 7% of China's population was identified as overweight; by 2006, this proportion had risen to 15%; today, one out of every four adults is overweight. In the past 15 years, 1.2% of people have become obese every year. The large increase in the number of obese people has brought tremendous momentum to the development of the Chinese weight loss market. It is a pity that the huge scale and rapid growth have not brought about a healthy development environment for the weight loss market in China. Issues such as illegal additions, “three nos” products, and false publicity were frequently exposed, constantly challenging the bottom line of consumers.

In the chaotic weight loss market environment, the emergence of Orlistat is undoubtedly a glimmer of hope for the majority of obese patients.

orlistat

Orlistat is a pancreatic lipase inhibitor that acts locally on the gastrointestinal tract and is the only non-central nerve action "weight loss drug". In 2010, Orlistat was approved by the State Food and Drug Administration and is currently the only weight-loss drug approved by the State Food and Drug Administration. Orlistat capsule is not only a weight-loss drug, it is also advocated for a uniform and healthy weight loss, by inhibiting the gastric lipase in the stomach and the activity of pancreatic lipase in the small intestine, and playing a weight-loss effect, many non-obese people also You can control your calorie intake by taking orlistat capsules and maintain a good body.

Yasu brand pushes Orlistat to a climax

As early as 2004, Chongqing Zhien Pharmaceutical began to develop Orlistat. After six years of unremitting efforts, the first domestic orlistat preparation was finally launched in 2010. During this period, Yasu's synthetic process route and key technologies have obtained a number of domestic and international invention patents, and its orlistat raw materials have also obtained the national new drug certificate, and have been approved for the national major new drug creation project.

Experts pointed out that through scientific experiments, in the control of the total impurity content, according to the ICH (International Committee for the Registration of Human Drugs Technology) and the US USP standard, the production of yoghurt orlistat capsules is more accurate and reduces side effects. The probability of occurrence is more secure. In response to the currently announced Orlistat production process, the R&D personnel of the Yasuo Orlistat capsules carried out a detailed analysis, and for the first time achieved the full synthesis of orlistat in China, and made significant progress in the synthesis process. Similarly, for the preparation method of Orlistat, the research and development personnel of Yasu Plastics conducted detailed and complete research and established a multi-center quality control system for the products, which made the production process of Orlistat more green.

In the past few months, Yasuo Orlistat capsules have won many praises in major pharmacies, and its future market prospects are worth looking forward to. Yasu Orlistat Capsule brings a new look to the domestic weight loss medicine market. It advocates a “safe and effective” weight loss concept, which makes consumers more rational to look at the variety of weight loss products on the market, and better realize The difference between weight loss health products and diet pills.